Royalty Pharma Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Royalty Pharma stock.
View analyst ratings for Royalty Pharma or view top-rated stocks.

Wall Street analysts have given Royalty Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Royalty Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Royalty Pharma saw a decrease in short interest in June. As of June 30th, there was short interest totaling 9,360,000 shares, a decrease of 30.3% from the June 15th total of 13,420,000 shares. Based on an average daily trading volume, of 1,880,000 shares, the short-interest ratio is currently 5.0 days. Approximately 3.1% of the shares of the company are short sold.
View Royalty Pharma's Short Interest.

Royalty Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Royalty Pharma.

Royalty Pharma will be holding an earnings conference call on Wednesday, August 11th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Royalty Pharma plc (NASDAQ:RPRX) issued its earnings results on Tuesday, May, 11th. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. The biopharmaceutical company had revenue of $524 million for the quarter, compared to the consensus estimate of $489.61 million. Royalty Pharma had a trailing twelve-month return on equity of 13.49% and a net margin of 44.35%.
View Royalty Pharma's earnings history.

Royalty Pharma declared a quarterly dividend on Monday, July 19th. Stockholders of record on Friday, August 20th will be paid a dividend of $0.17 per share on Wednesday, September 15th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.73%. The ex-dividend date is Thursday, August 19th.
View Royalty Pharma's dividend history.

Royalty Pharma pays an annual dividend of $0.68 per share and currently has a dividend yield of 1.71%. Royalty Pharma does not yet have a strong track record of dividend growth. The dividend payout ratio of Royalty Pharma is 42.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Royalty Pharma will have a dividend payout ratio of 21.59% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.
View Royalty Pharma's dividend history.

1 brokers have issued 12-month price objectives for Royalty Pharma's stock. Their forecasts range from $51.00 to $51.00. On average, they anticipate Royalty Pharma's share price to reach $51.00 in the next twelve months. This suggests a possible upside of 30.1% from the stock's current price.
View analysts' price targets for Royalty Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Royalty Pharma include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of RPRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), salesforce.com (CRM) and Twilio (TWLO).

(RPRX) raised $1.9 billion in an IPO on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX."

Shares of RPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RPRX stock can currently be purchased for approximately $39.20.

Royalty Pharma has a market capitalization of $23.80 billion and generates $2.12 billion in revenue each year. The biopharmaceutical company earns $975.04 million in net income (profit) each year or $1.61 on an earnings per share basis.

Royalty Pharma was founded in 1996.

The official website for Royalty Pharma is www.royaltypharma.com.

Royalty Pharma is headquartered at 110 E 59th Street, New York NY, 10022.

Royalty Pharma's mailing address is 110 E 59th Street, New York NY, 10022. The biopharmaceutical company can be reached via phone at 212-883-0200 or via email at [email protected]